ClinicalTrials.gg
CompletedNCT05443984Updated Aug 27, 2024

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

A Phase 3 interventional study of JP-1366 20mg and Esomeprazole 40mg in Erosive Esophagitis, sponsored by Onconic Therapeutics Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2022, registered Jun 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Esophagitis with a site in Korea, Republic of — none open to participants now, none under way, none of them phase 3. Esophagitis · Korea, Republic of.

Enrollment
6th of 12
300 · median 290
Started
2022
the only one that year
Phase 3
9 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Onconic Therapeutics Inc.

Among the 12 studies in Esophagitis with a site in Korea, Republic of, this one is the 6th largest by enrollment, is the only one that started in 2022, is one of 9 in phase 3, and was the 12th registered.

Esophagitis

123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.

Browse Esophagitis studies →

Open to participants now

None of the 12 studies in Esophagitis with a site in Korea, Republic of is open now. The open studies under Esophagitis, anywhere →

Who these studies take

Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Esophagitis with a site in Korea, Republic of as a file.
02

Study summary

To evaluate the efficacy and safety of JP-1366 20 mg compared to esomeprazole 40 mg in patients with erosive esophagitis

03

Conditions studied

  • Erosive Esophagitis

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Inclusion Criteria: Subjects must satisfy all the following criteria.

    1. Male or female, ≥ 19 years of age at the time of obtaining consent
    2. Subjects who had experienced heartburn and regurgitation within 7 days prior to the screening visit, those whose severity and frequency of symptoms fall under the following (1) or (2)

      ⑴ Subjects who have experienced mild or more severe heartburn or regurgitation at least twice a week

      ⑵ Subjects who have experienced moderate or more severe heartburn or regurgitation at least once a week

    3. Endoscopically confirmed grade A or higher erosive esophagitis as defined by †LosAngeles classification within 15 days, prior to randomization
    4. Subjects who fully understand this study and voluntarily signed on the form
  • Exclusion Criteria: Subjects may not satisfy any of the following criteria.

    1. Subjects who can't undergo endoscopy
    2. Medical History

      º Subjects who have warning symptoms of the malignant gastrointestinal tract such as odynophagia, severe dysphagia, bleeding, weight loss, anemia, or bloody stool. (except negative result for by endoscopy)

      º Subjects with eosinophilic esophagitis (except negative result by esophageal )

      º Subjects who have esophageal stenosis, gastroesophageal varices, Barrett's esophagus, active gastric ulcer, gastrointestinal bleeding, or malignant tumor confirmed by EGD

      º Zollinger-Ellison syndrome patients

      º Subjects diagnosed with primary esophageal motility disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or suspected with IBS in the last 3 months and with a current history of the disease including pancreatitis

      º Subjects who have a history of gastric acid suppression surgery, gastrointestinal or esophageal surgery (except appendectomy, cholecystectomy, polypectomy)

      º Subjects with a history of hepatic, renal, cardiovascular, respiratory, endocrine, urinary, neuro-psychiatric, hemato-oncologic disorder

      º Subjects who have a history of malignant tumor in 5 years at the time of screening. However, excluding subjects with malignant gastrointestinal cancer regardless of the period.

    3. Laboratory Test

      Screening laboratory test showing any of the following abnormal laboratory results:

      º or AST > 2.0 x

      º ALP or GGT > 2.0 x ULN

      º Total > 2.0 x ULN

      º \<70 mL/min/1.73 m2 (CKD-EPI formula)

      º Positive result for Serological test (, Ab, Ab, Syphilis reagin test)

      º Clinically significant abnormalities

    4. Allergy and drug

      º Known hypersensitivity to the active ingredient or of the product

      º Clinically significant allergies (except mild allergic rhinitis) or hypersensitivity history to drugs. (Aspirin, antibiotics, etc.)

    5. Prohibited medication and therapy

      º Subjects who take gastric acid suppressant like P-CAB, PPI within 2weeks prior to EGD of screening procedure

      º Subjects who take medication (antacids, prokinetics, H2RA, etc.) related to reflux esophagitis more than 2times within 1week prior to EGD of screening procedure

      º Subjects who need to take medication (aspirin, NSAIDs, etc.) that may cause an ulcer, during the study period

      º Subjects who are on or need to be on the medications which categorized as in this clinical trial.

      However, subjects who are on the contraindicated medications can participate in the trial after the of 2 weeks. If five times of the half-life of the contraindicated medications exceeds 2 weeks, the washout period will be set as five times of the half-life.

    6. Pregnant and lactating women
    7. Subjects who do not agree to use medically acceptable methods of contraception during the period study
    8. Subjects with clinically significant psychiatric disorder and a history with a drug and alcohol abuse.
    9. Subjects who are judged unsuitable to participate in the study in the opinion of the investigator
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Experimental Group

    JP-1366 20mg + Esomeprazole 40mg(placebo)

    Drug: JP-1366 20mg

  • Active comparator
    Active Comparative Group

    JP-1366 20mg(placebo) + Esomeprazole 40mg

    Drug: Esomeprazole 40mg

Interventions

  • 1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)

  • 1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)

06

What researchers measure

Primary outcomes

  1. The cumulative healing rate of mucosal break at 8-week after the investigational product administration (%)

    The proportion of subjects with remission on endoscopy at 8-week

    Time frame: Week 8

Secondary outcomes

  1. Healing rate of mucosal break at the 4-week after the investigational product administration

    The proportion of subjects whose mucosal breaks are healed on the 4-week endoscopy

    Time frame: Week 4

  2. Healing rate of mucosal break evaluated by an independent evaluator at the 4-week after the investigational product administration

    Time frame: Week 4

  3. The cumulative Healing rate of mucosal break evaluated by an independent evaluator at the 8-week after the investigational product administration

    Time frame: Week 8

  4. Symptom assessment according to the RDQ questionnaire

    Time frame: Week 4 and 8

  5. Gastro-esophageal symptoms assessment through subject diary at 4, 8 weeks

    Time frame: within 24hours after IP administration, during 7days after IP administration, Week 4 and 8

  6. Change from baseline in the total score of GERD-HRQL at 4, 8-week and cumulative changes in quality of life at 8week

    Time frame: Week 4 and 8

Other outcomes

  1. Exploratory variables

    Healing rate of mucosal break according to H.pylori infection

    Time frame: Week 4 and 8

07

Study locations

1 site
  • Asan Medical Center and 26 hospitals
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jan 2023, 11 months.

Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 5, 2022
StartActual
Jan 17, 2022
Primary completionActual
Jan 5, 2023
CompletionActual
Jan 5, 2023
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05443984
Responsible party
Sponsor
First posted
Jul 5, 2022
Start date
Jan 17, 2022
Primary completion
Jan 5, 2023
Completion
Jan 5, 2023
Last update
Aug 27, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zastaprazan

Start the discussion